Fuzionaire Theranostics is pioneering advancements in cancer treatment through its innovative HetSiFA® platform, which integrates diagnostic and therapeutic approaches in a personalized manner. This platform allows for the creation of chemically identical PET diagnostics and radioligand therapies, enabling tailored treatment for individual cancer patients. By utilizing fluorine-18 for PET diagnostics, Fuzionaire enhances the availability and resolution of imaging compared to traditional methods. The platform also employs alpha- and beta-emitting radionuclides, such as actinium-225, to deliver targeted therapies, thereby improving the efficacy of cancer care.

The company's pipeline focuses on developing complementary drug pairings that target specific markers on tumors, such as the gastrin-releasing peptide receptor (GRPR) in metastatic prostate cancer. This approach not only aims to improve the theranostic care of patients but also seeks to address the limitations of existing treatments by providing dual-targeting options. The modular nature of the HetSiFA® platform facilitates rapid expansion of the pipeline, allowing Fuzionaire to respond to critical needs in oncology and enhance the overall effectiveness of cancer diagnostics and therapies.

United States

Fuzionaire Theranostics is a radiopharmaceutical company on a mission to make theranostic treatments more accessible to people with cancer. With origins in Nobel laureate Robert Grubbs' lab at Caltech, the company's patented HetSiFA® platform offers manufacturing advantages in a clinical setting and enables a personalized therapeutic dose for each cancer patient. Current development plans address pressing clinical needs in prostate and lung cancer.

For more, visit us at: www.fuzionairetx.com

Fuzionaire Theranostics

Company Details